ILI

Calibrate Sets New Benchmark in Obesity Treatment: Demonstrates a Remarkable 18% Sustained Weight Loss for Members at 24 Months, Outperforming GLP-1 Medication Trials

Retrieved on: 
Wednesday, January 31, 2024
General Health, Diabetes, Other Health, Health, Fitness & Nutrition, Weight loss, Drug, Prediabetes, Obesity, MD, Sleep, Exercise, Patient, Doctor of Pharmacy, A1C, ILI, Result, Insurance, Pharmaceutical industry

Calibrate, the leading clinician-guided and value-based obesity treatment program, is releasing groundbreaking new results from the largest real-world member cohort yet, with program-wide weight loss surpassing outcomes observed in GLP-1 medication clinical trials.

Key Points: 
  • Calibrate, the leading clinician-guided and value-based obesity treatment program, is releasing groundbreaking new results from the largest real-world member cohort yet, with program-wide weight loss surpassing outcomes observed in GLP-1 medication clinical trials.
  • “The results from our largest-ever data cohort highlight Calibrate’s unique position in addressing the nation's obesity crisis,” said Scott Honken, PharmD, President & Chief Commercial Officer, Calibrate.
  • In addition, we’re extremely proud that 78% of members attained normal A1c levels after starting the program with diabetes or prediabetes.
  • Today’s Results Report shows that, among members who discontinued GLP-1, 92% maintained a clinically significant 10% weight loss at least six months post-tapering.

Koty Bogle Promoted to President of ENTEGRA®

Retrieved on: 
Wednesday, November 22, 2023
QHSE, Humble Oil, Acquisition, ILI, Engineering, Culture, Data analysis, UHR, Trust, Management

INDIANAPOLIS, Nov. 22, 2023 /PRNewswire/ -- Effective immediately, Koty Bogle has been promoted to the position of President of ENTEGRA.

Key Points: 
  • INDIANAPOLIS, Nov. 22, 2023 /PRNewswire/ -- Effective immediately, Koty Bogle has been promoted to the position of President of ENTEGRA.
  • As ENTEGRA has grown from startup to an industry leading, global in-line inspection service provider, this move is a natural progression from Bogle's current COO role, where he was responsible for global operations, data analysis, QHSE, and project management.
  • Current President and co-founder, Mark Olson, will step into the role of CEO and Chairman of the Board.
  • "I'm simultaneously humbled, honored, and excited for the trust and faith Mark and ENTEGRA's employees, founders, Board, and investors have placed in me to lead ENTEGRA," Bogle said.

BARDA Expands Partnership With Evidation to Validate and Improve Machine Learning Models for Early Detection of Influenza-like Illness Using Wearables

Retrieved on: 
Tuesday, October 17, 2023
Research, Pharmaceutical, Telemedicine, Virtual Medicine, Medical Devices, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Science, Biotechnology, Wearables, Mobile Technology, Health, COVID-19, Administration for Strategic Preparedness and Response, Disease, Development, Office of Inspector General, U.S. Department of Health and Human Services, PCR, Human services, Risk, Home, Biomedical Advanced Research and Development Authority, Administration, Sensor, Education, Urinary tract infection, Sleep, RSV, Respiratory syncytial virus, BARDA, Life, HHS, ILI, Heart Protection Study, Ill, Vaccine, Evidence-based policy

The Detect & Protect Studies will support the development of machine learning models to detect respiratory viral infections with data collected from consumer-grade wearable devices.

Key Points: 
  • The Detect & Protect Studies will support the development of machine learning models to detect respiratory viral infections with data collected from consumer-grade wearable devices.
  • This contract will also fund research to expand and better understand the potential impact of Evidation’s FluSmart program to encourage protective health behaviors.
  • This is the third BARDA award issued to Evidation to advance understanding and detection tools for respiratory infections.
  • In 2020, BARDA funded follow-on research to investigate if and how machine learning models and novel data from wearables could be used to detect symptoms of COVID-19 infection .

Successful Indigenous Guardians initiatives now in over a quarter of First Nations across Canada

Retrieved on: 
Friday, September 29, 2023
Knowledge, Tradition, Interim, Partnership, United Nations, The Honourable, Culture, Guilbeault, Water quality, ILI, Environment and Climate Change Canada, Climate change, Elder, ECCC, Language, Indigenous peoples, Plant, Biodiversity, Biodiversity loss, Ice, Animal, Investment, Kitigan Zibi, Risk, Kitigan Zibi Anishinabeg, Council, Economic development, Indigenous self-government in Canada, First Nations, Environment, Federation, Guardian, Agriculture, Mining, Tourism, Earth

This investment will support 41 new and 49 existing First Nations Indigenous Guardians initiatives to protect and conserve lands, waters, and culture while providing meaningful employment opportunities.

Key Points: 
  • This investment will support 41 new and 49 existing First Nations Indigenous Guardians initiatives to protect and conserve lands, waters, and culture while providing meaningful employment opportunities.
  • With these new initiatives, over a quarter of all First Nation communities will now have active Guardians programs from coast to coast to coast.
  • Expanding the Guardians model across the country will help build a better, shared future for First Nations and Canada."
  • The federal government expanded its support for Indigenous Guardians in 2021, committing up to $100 million to support new and existing Indigenous Guardians initiatives.

MISTRAS Announces Second Quarter and First Half 2023 Results

Retrieved on: 
Wednesday, August 2, 2023
Project Phoenix, Electricity generation, Capital expenditure, International, SG, Defense, ILI, GAAP, History, Downstream, Public expenditure, NYSE, Gas, EBITDA, PIN, MG, FX, Investment, Workload, Century, Growth, Free cash flow, Bookkeeping, Commercial property, Cryptocurrency, Video game, Rare-earth element, Pharmaceutical industry, OnStream, Aerospace, Adjustment

PRINCETON JUNCTION, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its second quarter and six months ended June 30, 2023.

Key Points: 
  • Second quarter 2023 gross profit decreased 7.2% with gross profit margin declining 170 basis points, as compared to the year ago period.
  • Selling, general and administrative expenses (“SG&A”) in the second quarter of 2023 were $41.5 million, up from $40.9 million in the second quarter of 2022, in part due to aforementioned unfavorable FX exchange.
  • Second quarter SG&A was down sequentially from the first quarter of 2023, as a result of on-going budgeted cost controls.
  • Gross profit margin was 27.3% for the second quarter of 2023, a 140 basis point decline from 28.7% in the second quarter of the prior year.

MISTRAS Announces First Quarter 2023 Results

Retrieved on: 
Wednesday, May 3, 2023
Capital expenditure, International, SG, Service, Segment, ILI, OnStream, AGC Aerospace & Defense, NYSE, Sensoria Music & Film Festival, EBITDA, PIN, Acquisition, MG, Investment, Upstream, Aerospace, Flagship, Growth, Cryptocurrency, Bookkeeping, Video game, Pharmaceutical industry, Defense, New Century Financial

PRINCETON JUNCTION, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its first quarter of 2023.

Key Points: 
  • Revenue increase of 3.9% as reported; up 5.5% in constant currency
    PRINCETON JUNCTION, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its first quarter of 2023.
  • Selling, general and administrative expenses in the first quarter of 2023 were $42.8 million, up from $41.9 million in the first quarter of 2022, yet down as a percentage of revenue.
  • Our Onstream inline inspection testing (ILI) business has continued its record 2022 performance into the first quarter of 2023.
  • Gross profit margin was 26.8% for the first quarter of 2023, a 380 basis point improvement from 23.0% in the first quarter of the prior year.

BlueDot's latest offering empowers pharma and life science organizations to stay ahead of influenza and COVID disruptions

Retrieved on: 
Thursday, April 27, 2023
COVID-19, Organization, Infection, Season, Weather, Death, ILI, BlueDot, Intelligence, ILIS, Public, Disease, Vaccine

TORONTO, April 27, 2023 /PRNewswire-PRWeb/ -- BlueDot Inc., a leading organization that uses artificial and human intelligence to detect, assess, and respond to infectious disease threats worldwide, has introduced an innovative new Influenza-like-illness (ILI) business offering. The intelligence products are designed to help organizations mitigate the impact of respiratory viruses like influenza and COVID-19, by providing expert guidance and valuable insights to reduce disruption and safeguard public health.

Key Points: 
  • The intelligence products are designed to help organizations mitigate the impact of respiratory viruses like influenza and COVID-19, by providing expert guidance and valuable insights to reduce disruption and safeguard public health.
  • ILIs are highly contagious and can impact as much as 20 percent* of the population during the winter months.
  • BlueDot has launched a dedicated ILI intelligence offering timely, comprehensive insights to anticipate, assess, and act against ILI risks.
  • To learn more about ILI insights and intelligence, request an overview from [email protected] or visit our website here.

Metabolic Health Program Combining GLP-1 Medication with Behavior Change Publishes Annual Results Demonstrating 15% Average Weight Loss at 12, 18, & 24 Months and Reversal of Diabetes or Prediabetes Diagnosis in 81% of Participants

Retrieved on: 
Tuesday, February 21, 2023
Managed Care, Diabetes, Fitness & Nutrition, Health, Clinical trial, European Master Program in Computational Logic, Enterprise, MD, Weight loss, Waist, Pennington Biomedical Research Center, Insurance, Metabolic syndrome, Editor-in-chief, Metabolism, Health insurance coverage in the United States, ILI, Patient, Liraglutide, Biology, STEP, Prediabetes, Report, BMI, Overweight, Pharmaceutical industry, Nursing, Medical device, Calibration, Obesity

Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.

Key Points: 
  • Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.
  • The clinically-reviewed data demonstrates overall metabolic health improvements, and notably, the reversal of diabetes and prediabetes diagnoses in 81% of members.
  • “Our most recent Results Report validates our initial vision: that a comprehensive program combining medication with behavior change is the standard of care for obesity treatment.
  • “This is remarkable because it shows more sustained weight loss than the STEP 5 trials using Wegovy––while using a variety of different GLP-1 medications.

Andes and IAR Systems Together Enable Leading Vendor ILITEK to Accelerate the Development of its ISO 26262 Ready TDDI SoC ILI6600A

Retrieved on: 
Tuesday, February 14, 2023
ASIL, IAR Systems, Somatosensory system, AEC, ESD, ISO, System, Andes Technology, MCU, Safety, Algorithm, EMS, Engineering, Ecosystem, SOC, Automotive engineering, ILI, LCD, IIE, CPU, Partnership, EMI, SNR, IAR, Environment, Longhe, Chongqing, Knob, Longevity, Mobile phone, Automotive industry

The joint solution from Andes and IAR Systems is ISO 26262-certified with robust design methodology.

Key Points: 
  • The joint solution from Andes and IAR Systems is ISO 26262-certified with robust design methodology.
  • The LCD driver in ILI6600A supports up to 3 chips cascading and provides the number of colors up to 16.7M.
  • “The ILI6600A is our first ISO 26262 ASIL B ready product which provides robust, real-time and certified Fail detection functions.
  • The functional safety edition of IAR Embedded Workbench for RISC-V is certified by TÜV SÜD according to ten different standards, including ISO 26262.

R. Douglas Leonard Jr. Appointed to Lead ANAB as Executive Director

Retrieved on: 
Wednesday, November 16, 2022
Quality of life, International Accreditation Forum, Non-functional testing, Growth, NVLAP, Trust, American National Standards Institute, International Electrotechnical Commission, Goal, ANSI, General officer, Laboratory, National Institute, International Organization (journal), Cross-national cooperation and agreements, Committee, IAF, National Voluntary Laboratory Accreditation Program, Organization, Leadership, National Committee, Calibration, ISO, NIST, View, ISO/IEC 17025, Policy, Institute, Accreditation, Multimedia, CASCO, Technology, IEC, Government, NACLA, CEO, ASTM, ISO/IEC, International Laboratory Accreditation Cooperation, National, APAC, ILI, IAAC, ILAC, Property management, Management, Angela Merkel

NEW YORK, Nov. 16, 2022 /PRNewswire/ -- The American National Standards Institute (ANSI) is pleased to announce that R. Douglas Leonard Jr. has been appointed as executive director of its wholly owned subsidiary, the ANSI National Accreditation Board (ANAB), effective November 21. ANAB is the largest multi-disciplinary ISO/IEC 17011 accreditation body in North America, with comprehensive signatory status across the multilateral recognition arrangements of the International Accreditation Forum (IAF) and International Laboratory Accreditation Cooperation (ILAC).

Key Points: 
  • has been appointed as executive director of its wholly owned subsidiary, the ANSI National Accreditation Board (ANAB), effective November 21.
  • As executive director, Leonard will provide the strategic leadership to position ANAB at the forefront of international accreditation, assuring the integrity of services, advancing ANAB's vision and mission, and striving for sustained growth and diversification.
  • A veteran of the conformity assessment community, Leonard has served as co-interim executive director of ANAB since December 2021 and in the capacity of ANAB vice president of product, inspection, laboratory, and related activities since 2015.
  • ANAB also announced that Warren Merkel will join ANAB as vice presidentpolicy, effective November 21.